Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04590248 · ClinicalTrials.gov registry record · Phase 2

A Study of Adavosertib as Treatment for Uterine Serous Carcinoma

A Phase 2 study of Uterine Serous Carcinoma, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
109
Enrollment target
20
Study locations

NCT04590248 is a Phase 2 study of Uterine Serous Carcinoma that has completed, run by AstraZeneca. The registered enrollment target is 109 participants, above the 85-participant average among 4 other Uterine Serous Carcinoma trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04590248, a Phase 2 study of Uterine Serous Carcinoma, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
109 participants
Enrollment target
20
Study locations

Study Summary

This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.

Conditions Studied

Uterine Serous Carcinoma

Interventions

  • DRUG Adavosertib

Study Locations (20)

Other

  • Research Site - Toronto
  • Research Site - Dijon
  • Research Site - Marseille
  • Research Site - Nice
  • Research Site - Pierre-Bénite
  • Research Site - Saint-Herblain

California

  • Research Site - Burbank
  • Research Site - Duarte
  • Research Site - La Jolla
  • Research Site - West Hollywood

New York

  • Research Site - New York
  • Research Site - The Bronx

Washington

  • Research Site - Spokane
  • Research Site - Vancouver

Colorado

  • Research Site - Aurora

Iowa

  • Research Site - Iowa City

Louisiana

  • Research Site - Covington

Massachusetts

  • Research Site - Boston

Trial Details

FieldValue
Enrollment Target 109 participants
Start Date 2020-11-30
Est. Completion 2023-02-07
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04590248

The ClinicalTrials.gov registry entry for NCT04590248 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 85-participant average among 4 other Uterine Serous Carcinoma trials with a reported enrollment target (28% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Uterine Serous Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Adavosertib is the first listed.

NCT04590248 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, New York.

Frequently Asked Questions

What is clinical trial NCT04590248 about?

NCT04590248 is a clinical study titled "A Study of Adavosertib as Treatment for Uterine Serous Carcinoma". This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.

What is the current status of trial NCT04590248?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2020-11-30. Estimated completion is 2023-02-07.

What conditions does trial NCT04590248 study?

This clinical trial studies the following conditions: Uterine Serous Carcinoma.

What interventions are being tested in trial NCT04590248?

The interventions under investigation include: Adavosertib (DRUG).

Who is sponsoring clinical trial NCT04590248?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04590248 being conducted?

This trial has 20 study locations across California, Colorado, Iowa, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Uterine Serous Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Uterine Serous Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.